Central Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Youth

2.50
Hdl Handle:
http://hdl.handle.net/10755/151863
Type:
Presentation
Title:
Central Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Youth
Abstract:
Central Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Youth
Conference Sponsor:Sigma Theta Tau International
Conference Year:2003
Conference Date:July 10-12, 2003
Author:Appel, Susan
Co-Authors:Joanne S. Harrell, Jianhua Hu
Objective: To determine the relationship of central obesity with the Metabolic Syndrome (MS) (hyperinsulinemia, hypertension, hypertriglyceridemia, and low HDL-C), and plasma levels of Plasminogen Activator Inhibitor-1 (PAI-1) in youth age 18-22.<P> Design: Cross-sectional descriptive study. Population: 85 subjects who had participated in the Cardiovascular Health in Children study, 53 females and 32 males, mean age 19.6.<P> Concept: Central obesity is the cornerstone of the MS that may lead to type 2 diabetes (T2D) and cardiovascular disease (CVD). PAI-1 is associated with vascular injury and is a new candidate as a risk factor for CVD, and as a component of the MS however, little is known regarding this syndrome during youth.Methods: Subjects fasted for 12-hours, waist circumference (as measure of central obesity), BP were obtained along with labs. <P> Findings: Over half of the subjects had one or more components of the MS (58.2%). Central obesity was present in 14.1%, and in more females (X2 = 5.11; p = 0.021). Waist circumference was significantly correlated with BP, insulin, PAI-1 and low HDL-C. More subjects with central obesity had hyperinsulinemia (25%, X2 = 12.26; p = 0.009) and hypertension (41.7%, X2 = 10.23; p = 0.007). Multiple regression determined the most efficient model for predicting waist circumference. Predictors were diastolic BP, insulin and HDL-C, (R2 = 0.572). An additional predictor of central obesity was family history of T2D. In a separate regression, PAI-1 was predicted by waist circumference (R2 = 0.276). Conclusion: Screening for central obesity, MS and PAI-1 levels should be considered before adulthood and especially in those with first-degree relatives with T2D.<P> Implications: Measurement of waist circumference as a screening for central obesity should be performed during routine well exams and youth with central obesity should be further screened for MS.
Repository Posting Date:
26-Oct-2011
Date of Publication:
10-Jul-2003
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleCentral Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Youthen_GB
dc.identifier.urihttp://hdl.handle.net/10755/151863-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Central Obesity, the Metabolic Syndrome and Plasminogen Activator Inhibitor-1 in Youth</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2003</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">July 10-12, 2003</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Appel, Susan</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">appel@email.unc.edu</td></tr><tr class="item-co-authors"><td class="label">Co-Authors:</td><td class="value">Joanne S. Harrell, Jianhua Hu</td></tr><tr><td colspan="2" class="item-abstract">Objective: To determine the relationship of central obesity with the Metabolic Syndrome (MS) (hyperinsulinemia, hypertension, hypertriglyceridemia, and low HDL-C), and plasma levels of Plasminogen Activator Inhibitor-1 (PAI-1) in youth age 18-22.&lt;P&gt; Design: Cross-sectional descriptive study. Population: 85 subjects who had participated in the Cardiovascular Health in Children study, 53 females and 32 males, mean age 19.6.&lt;P&gt; Concept: Central obesity is the cornerstone of the MS that may lead to type 2 diabetes (T2D) and cardiovascular disease (CVD). PAI-1 is associated with vascular injury and is a new candidate as a risk factor for CVD, and as a component of the MS however, little is known regarding this syndrome during youth.Methods: Subjects fasted for 12-hours, waist circumference (as measure of central obesity), BP were obtained along with labs. &lt;P&gt; Findings: Over half of the subjects had one or more components of the MS (58.2%). Central obesity was present in 14.1%, and in more females (X2 = 5.11; p = 0.021). Waist circumference was significantly correlated with BP, insulin, PAI-1 and low HDL-C. More subjects with central obesity had hyperinsulinemia (25%, X2 = 12.26; p = 0.009) and hypertension (41.7%, X2 = 10.23; p = 0.007). Multiple regression determined the most efficient model for predicting waist circumference. Predictors were diastolic BP, insulin and HDL-C, (R2 = 0.572). An additional predictor of central obesity was family history of T2D. In a separate regression, PAI-1 was predicted by waist circumference (R2 = 0.276). Conclusion: Screening for central obesity, MS and PAI-1 levels should be considered before adulthood and especially in those with first-degree relatives with T2D.&lt;P&gt; Implications: Measurement of waist circumference as a screening for central obesity should be performed during routine well exams and youth with central obesity should be further screened for MS.</td></tr></table>en_GB
dc.date.available2011-10-26T11:16:13Z-
dc.date.issued2003-07-10en_GB
dc.date.accessioned2011-10-26T11:16:13Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.